Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Century Therapeutics Inc. Common Stock
IPSC | US
2.17
USD-0.19
-8.05%
IPSC | US
Loading StockChartView...
About Century Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
2.17
Open
2.35
High
2.35
Low
2.14
Century Therapeutics Inc. a biotechnology company develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101 an allogeneic induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed refractory B-cell lymphoma. It is also developing CNTY-102 a CAR-iT targeting CD19 + CD22 for relapsed refractory B-cell lymphoma and other B-cell malignancies; CNTY-107 an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104 a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106 a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics Inc. was incorporated in 2018 and is headquartered in Philadelphia Pennsylvania.
View LessIPSC | US
Risk
58.9
Sharpe
3.09
Luna's Score
51/100
Recommendation
Hold
Luna says (IPSC | US)
What's Working
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
81.8%1 month
58.9%3 months
77.9%6 months
124.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.60
Debt to equity
0.25
Debt to assets
0.14
Ent. to EBITDA
0.08
Ent. to rev.
1.96
PEG
-
Other Fundamentals
EBITDA
-114.72M
MarketCap
183.83M
MarketCap(USD)
183.83M
Div. yield
-
Op. margin
-4.51K
Erngs. growth
-
Rev. growth
678.80
Ret. on equity
-55.95
Short ratio
9.41
Short perc.
5.05
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.42
Range1M
0.42
Range3M
1.11
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.34
Price X volume
2.39M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.08 | 0.53 | Cheaper |
| Ent. to Revenue | 1.96 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.60 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 77.85 | 72.80 | Par |
| Debt to Equity | 0.25 | -1.23 | Expensive |
| Debt to Assets | 0.14 | 0.25 | Cheaper |
| Market Cap | 183.83M | 3.66B | Emerging |
